Track Disc Medicine Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Disc Medicine Inc. Common Stock IRON · Stock Open Disc Medicine Inc. Common Stock in new tab

80.00 USD
EPS
-6.10
P/B
5.11
ROE
-41.29
Beta
2.01
Target Price
126.77 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-6.10
Book Value15.65
Price to Book5.11
Debt/Equity10.11
% Insiders6.559%
Estimates
Forward P/E-12.80
Forward EPS-6.25
Target Mean Price126.77

DCF valuation

Model fair value for Disc Medicine Inc. Common Stock (IRON)
Result
Sign in to run the valuation for IRON.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Strong buy · mean target 126.77 USD (low 92.00, high 170.00) · as of 16 Nov 2026
Low 92.00
Mean 126.77
High 170.00
Price 80.00
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Disc Medicine Inc. Common Stock Logo Disc Medicine Inc. Common Stock Analysis (IRON)

United States Health Care Official Website Stock

Is Disc Medicine Inc. Common Stock a good investment? Disc Medicine Inc. Common Stock (IRON) is currently trading at 80.00 USD. Market analysts have a consensus price target of 126.77 USD. This suggests a potential upside from current levels.

Earnings Schedule: Disc Medicine Inc. Common Stock is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -6.25.

Investor FAQ

Does Disc Medicine Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Disc Medicine Inc. Common Stock?

Disc Medicine Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -6.10.

Company Profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Exchange Ticker
NMS (United States) IRON
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 30, 2022 0.03
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion